After the implementation of the Value-Added Tax Law, the preferential import tax policy will continue.

According to the Ministry of Finance, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation jointly issued a notice to ensure a smooth transition of import value-added tax preferential policies after the implementation of the "People's Republic of China Value-Added Tax Law." The current import value-added tax preferential policies will continue to be implemented. Among them, the value-added tax policies for anti-cancer drugs and rare disease drugs will be extended until the end of 2027. In addition, other preferential policies that have been implemented before the new law and have expiration dates after 2026 will also continue to be implemented according to the original regulations.